Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the potential cost to the public purse of the NHS providing semaglutide injections to eligible individuals in the next 12 months.
We have made no such estimate, as the information is not held in the format requested. Semaglutide is licensed for treatment for patient with type 2 diabetes and for weight management for some cohorts of patients alongside a reduced-calorie diet and increased physical activity in adults.